{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:41:49Z","timestamp":1760906509240,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.coms.2021.11.001","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T17:10:41Z","timestamp":1649351441000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Regional Lymph Nodes in Head and Neck Melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Mica D.E.","family":"Glaun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zipei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Lango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CMR.0b013e328351fa4d","article-title":"A\u00a0brief history of melanoma: from mummies to mutations","volume":"22","author":"Rebecca","year":"2012","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1016\/j.coms.2021.11.001_bib2","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1002\/hed.26398","article-title":"Updates in the evidence-based management of cutaneous melanoma","volume":"42","author":"Goepfert","year":"2020","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.coms.2021.11.001_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hed.1112","article-title":"Do nodal metastases from cutaneous melanoma of the head & neck follow a clinicall predictable pattern?","volume":"23","author":"Pathak","year":"2001","journal-title":"Head Neck"},{"key":"10.1016\/j.coms.2021.11.001_bib4","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"1012","author":"Rastrelli","year":"2014","journal-title":"In\u00a0Vivo (Brooklyn)"},{"issue":"5","key":"10.1016\/j.coms.2021.11.001_bib5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2014.06.046","article-title":"Indoor tanning in businesses and homes and risk of melanoma and non-melanoma skin cancer in two US case-control studies","volume":"71","author":"Ferrucci","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib6","article-title":"Perceptions of tanning risk among melanoma patients with a history of indoor tanning","volume":"101","author":"Nergard-martin","year":"2018","journal-title":"Cutis"},{"issue":"16","key":"10.1016\/j.coms.2021.11.001_bib7","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17, 600 melanoma patients: melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.001_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"13","key":"10.1016\/j.coms.2021.11.001_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archsurg.2009.271","article-title":"Predictors of occult nodal metastasis in patients with thin melanoma","volume":"145","author":"Faries","year":"2010","journal-title":"Arch Surg"},{"issue":"8","key":"10.1016\/j.coms.2021.11.001_bib11","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.coms.2021.11.001_bib12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.coms.2021.11.001_bib13","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.coms.2021.11.001_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/cncr.26288","article-title":"Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma","volume":"118","author":"Erman","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2021.11.001_bib17","article-title":"Impact of completion lymphadenectomy on quality of life for head and neck cutaneous melanoma","author":"Farlow","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.coms.2021.11.001_bib18","first-page":"341","article-title":"Malignant melanoma of unknown primary origin","volume":"117","author":"Das Gupta","year":"1963","journal-title":"Surg Gynecol Obstet"},{"issue":"13","key":"10.1016\/j.coms.2021.11.001_bib19","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","article-title":"Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site","volume":"21","author":"Gos","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2007.14.0285","article-title":"Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma","volume":"26","author":"Lee","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.coms.2021.11.001_bib21","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.21835","article-title":"Metastatic melanoma to lymph nodes in patients with unknown primary sites","volume":"106","author":"Cormier","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.coms.2021.11.001_bib22","doi-asserted-by":"crossref","first-page":"e1677139","DOI":"10.1080\/2162402X.2019.1677139","article-title":"Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results","volume":"8","author":"Gambichler","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.32229","article-title":"Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study","volume":"146","author":"Verver","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","article-title":"Clinical and immune profiling for cancer of unknown primary site","volume":"7","author":"Haratani","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.coms.2021.11.001_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.coms.2021.11.001_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3","article-title":"Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma","volume":"19","author":"O'Brien","year":"1997","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cncr.11921","article-title":"Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck","volume":"100","author":"Bonnen","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijrobp.2005.06.030","article-title":"Combined-modality therapy for patients with regional nodal metastases from melanoma","volume":"64","author":"Ballo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5826\/dpc.0901a03","article-title":"Melanoma: diagnostic and management implications","volume":"9","author":"Rossi","year":"2019","journal-title":"Dermatol Pr Concept"},{"issue":"6","key":"10.1016\/j.coms.2021.11.001_bib30","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hed.21238","article-title":"Role of postoperative irradiation for patients with bilateral cervical nodal metastases from cutaneous melanoma: a critical assessment","volume":"32","author":"Guadagnolo","year":"2010","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.coms.2021.11.001_bib31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hed.20233","article-title":"Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease?","volume":"27","author":"Ballo","year":"2005","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.coms.2021.11.001_bib32","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/archotol.129.8.864","article-title":"The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region","volume":"129","author":"Owens","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25482-w","article-title":"Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity","volume":"8","author":"Crittenden","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.coms.2021.11.001_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/21624011.2014.955696","article-title":"Tumor immune remodeling by TGF\u03b2 inhibition improves the efficacy of radiation therapy","volume":"4","author":"Young","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.coms.2021.11.001_bib36","first-page":"1","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"year":"1950","series-title":"The immune system","author":"Parham","key":"10.1016\/j.coms.2021.11.001_bib37"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.coms.2021.11.001_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.coms.2021.11.001_bib41","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.4049\/jimmunol.168.9.4420","article-title":"CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases","volume":"168","author":"Guntermann","year":"2002","journal-title":"J\u00a0Immunol"},{"issue":"17","key":"10.1016\/j.coms.2021.11.001_bib42","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.95.17.10067","article-title":"CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma","volume":"95","author":"Hurwitz","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5256","key":"10.1016\/j.coms.2021.11.001_bib43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.coms.2021.11.001_bib44","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.coms.2021.11.001_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"issue":"7","key":"10.1016\/j.coms.2021.11.001_bib46","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"10.1016\/j.coms.2021.11.001_bib47","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10240","key":"10.1016\/j.coms.2021.11.001_bib49","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2021.11.001_bib50","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3's enigmatic mechanism of action","volume":"11","author":"Graydon","year":"2021","journal-title":"Front Immunol"},{"issue":"15_suppl","key":"10.1016\/j.coms.2021.11.001_bib51","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047)","volume":"39","author":"Lipson","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.coms.2021.11.001_bib52","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/eji.200425887","article-title":"Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango","volume":"35","author":"Scheffold","year":"2005","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.coms.2021.11.001_bib53","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","article-title":"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells","volume":"162","author":"Curtsinger","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coms.2021.11.001_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.coms.2021.11.001_bib55","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"issue":"3","key":"10.1016\/j.coms.2021.11.001_bib56","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.173.3.647","article-title":"Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes","volume":"173","author":"Barth","year":"1991","journal-title":"J\u00a0Exp Med"},{"issue":"15","key":"10.1016\/j.coms.2021.11.001_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A\u00a0progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.coms.2021.11.001_bib58","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/83.13.932","article-title":"Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response","volume":"83","author":"Aebersold","year":"1991","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J\u00a0Immunother"},{"issue":"4","key":"10.1016\/j.coms.2021.11.001_bib60","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"10.1016\/j.coms.2021.11.001_bib61","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","article-title":"Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook","volume":"18","author":"Wu","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.coms.2021.11.001_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-015-0091-z","article-title":"Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma","volume":"3","author":"Feng","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.coms.2021.11.001_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2015.11.009","article-title":"OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment","volume":"52","author":"Bell","year":"2016","journal-title":"Oral Oncol"},{"issue":"24","key":"10.1016\/j.coms.2021.11.001_bib65","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.coms.2021.11.001_bib66","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2010.09.013","article-title":"Signaling through OX40 enhances antitumor immunity","volume":"37","author":"Jensen","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.coms.2021.11.001_bib67","doi-asserted-by":"crossref","first-page":"vi361","DOI":"10.1093\/annonc\/mdw378.07","article-title":"Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors","volume":"27","author":"Glisson","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.coms.2021.11.001_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.cgt.7700670","article-title":"Role of 4-1BB:4-1BB ligand in cancer immunotherapy","volume":"11","author":"Cheuk","year":"2004","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.coms.2021.11.001_bib69","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.coms.2021.11.001_bib70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.190.10.1535","article-title":"Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in\u00a0vivo through the induction of helper T cell anergy","volume":"190","author":"Mittler","year":"1999","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.coms.2021.11.001_bib71","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.coms.2021.11.001_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00000478-198702000-00008","article-title":"Malignant melanoma primary in lymph node. The case of the missing link","volume":"11","author":"Shenoy","year":"1987","journal-title":"Am J Surg Pathol"},{"issue":"29","key":"10.1016\/j.coms.2021.11.001_bib73","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.3748\/wjg.v13.i29.4027","article-title":"Malignant gastrointestinal melanomas of unknown origin: should it be considered primary?","volume":"13","author":"Manouras","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"7528","key":"10.1016\/j.coms.2021.11.001_bib74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"200","key":"10.1016\/j.coms.2021.11.001_bib75","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369921001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369921001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:13:28Z","timestamp":1760904808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369921001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1042369921001023"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2021.11.001","relation":{},"ISSN":["1042-3699"],"issn-type":[{"type":"print","value":"1042-3699"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Regional Lymph Nodes in Head and Neck Melanoma","name":"articletitle","label":"Article Title"},{"value":"Oral and Maxillofacial Surgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coms.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}